3D Cardiac Mapping Systems Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 538.60 Million |
| Market Size (2029) | USD 924.07 Million |
| CAGR (2024 - 2029) | 11.40 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
3D Cardiac Mapping Systems Market Analysis
The 3D Cardiac Mapping Systems Market size is estimated at USD 538.60 million in 2024, and is expected to reach USD 924.07 million by 2029, growing at a CAGR of 11.40% during the forecast period (2024-2029).
The major factors driving the market are the rising prevalence of cardiovascular diseases coupled with the rising geriatric population, the increasing technological advancements, and growing government organizations' initiatives to create awareness about cardiovascular diseases.
The rising prevalence of cardiovascular diseases coupled with the rising geriatric population is expected to drive demand for the 3D cardiac mapping system to diagnose cardiovascular diseases such as tachyarrhythmias and atrial fibrillation, which is expected to drive the market during the forecast period. For instance, according to an article published in the Lancet in February 2024, atrial fibrillation (AF) was more prevalent, with a lifetime risk of about 1 in 3-5 individuals after the age of 45 years. Projection studies reported that the prevalence of AF is expected to rise to 15.9 million in 2050 in America and 17.9 million in 2060 in Europe.
Similarly, according to StatPearls updated data from July 2023, ventricular tachycardia is strongly associated with coronary artery disease; around 15% of patients with coronary artery disease have ventricular tachycardia. Hence, the significant prevalence of cardiovascular diseases is expected to drive the market's growth during the forecast period.
The increasing technological advancements in 3D cardiac mapping systems are expected to increase the adoption of this system for diagnosing various diseases, which will ultimately drive the growth of the market during the forecast period. For instance, according to an article published in the Frontiers in April 2023, fluoroscopy integrated 3D mapping. A new 3D non-fluoroscopic navigation system software (CARTO Univu Module) was integrated into the 3D mapping systems to reduce radiation exposure during radiofrequency catheter ablation (RFCA). Hence, such incorporation of navigation software in cardiac mapping systems is expected to drive the growth of the market during the forecast period.
Also, according to an article published in October 2022, 3D nuclear imaging was integrated into the 3D mapping system to identify low-voltage proarrhythmic areas for catheter ablation of scar-mediated ventricular tachycardia (VT). Hence, such technological advancements are expected to drive the market during the forecast period.
Thus, the above-mentioned factors, including the rising prevalence of cardiovascular diseases and increasing technological advancements in 3D mapping systems, are expected to drive the growth of the market during the forecast period. However, the high cost of 3D cardiac mapping systems is expected to restrain the market during the forecast period.
3D Cardiac Mapping Systems Market Trends
The Electroanatomical Mapping Segment is Expected to Hold Significant Market Share During the Forecast Period
Electroanatomical mapping systems use mapping catheters to estimate the electrical activity of cardiac muscle and create comprehensive three-dimensional electroanatomic maps of patients' hearts. The clinical advantages of the electroanatomical mapping system and increasing technological advancements are expected to drive the segment's growth during the forecast period.
The clinical advantages of the electroanatomical mapping systems, including enhanced diagnostic accuracy, improved treatment outcomes, minimized procedure time, and others, are expected to fuel the demand for these systems during the forecast period. For instance, according to an article published in the Indian Pacing Electrophysiol Journal in February 2022, the electroanatomical mapping technology has been reported to decrease fluoroscopic exposure and radiation dose, with less significant effects on procedural duration time and success rates.
In addition, according to the same source mentioned above, several electroanatomical mapping (EAM) systems have advanced features, such as improved ability to map non-sustained or hemodynamically unstable arrhythmias, ability to display diagnostic and mapping catheter positions, and wide compatibility with a variety of catheters. Hence, such clinical advantages of the EAM technological systems are anticipated to drive the growth of this segment in the coming years.
Also, the increasing technological advancements in EAM technologies are expected to drive the segment growth during the forecast period. For instance, according to an article published in HeartRhythm Case Reports in October 2023, the use of an electroanatomic mapping system with high-density multipolar mapping catheters to guide transvenous atrial pacing lead implantation in a Fontan patient is increasing, which ultimately raises the demand for the electroananatomical 3D mapping devices. Hence, this factor is likely to propel the growth of the segment during the forecast period.
Hence, clinical advantages of the electroanatomic mapping system and increasing technological advancements are expected to drive the segment growth during the forecast period.
North America is Expected to Hold the Significant Market Share During the Forecast Period
The geographical analysis of the 3D cardiac mapping system market shows that North America holds a significant market share in the global market. This is due to the rising prevalence of various cardiovascular diseases in the region, the presence of prominent players, and the increasing number of product launches.
The growing burden of cardiovascular diseases in North America is expected to drive market growth during the forecast period. For instance, as per the report published by Scripps Health in January 2022, approximately one in 18 people, or 5% of the United States population, had an arrhythmia in 2022. It also highlighted that one in four adult Americans over the age of 40 have a possibility of developing an irregular heartbeat. Hence, the high prevalence of cardiovascular diseases is anticipated to augment the growth of the market in the coming years.
Also, increasing strategic activities such as product launches and acquisitions are expected to drive the market during the forecast period. For instance, in August 2022, Medtronic, a medical device company, acquired Affera Inc., a medical technology that provides cardiac arrhythmia treatment devices. This acquisition expanded the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform encompassing a differentiated, fully integrated diagnostic, focal pulsed field, and radiofrequency ablation solution. Hence, such product launches are also likely to drive the growth of the market during the forecast period.
Thus, North America is expected to witness significant growth during the forecast period due to the above-mentioned factors, such as the rising prevalence of cardiovascular diseases and increasing strategic activities such as product launches.
3D Cardiac Mapping Systems Industry Overview
The 3D cardiac mapping systems market is fragmented due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of several international and local companies that hold market shares and are well known, including Olympus Corporation, Medtronic, GE Healthcare, Siemens Healthiness AG, and Smith + Nephew. Abbott, Intuitive Surgical Inc., Koninklijke Philips NV, Stryker, and Zimmer Biomet.
3D Cardiac Mapping Systems Market Leaders
-
Koninklijke Philips NV
-
Zimmer Biomet
-
Medtronic
-
Smith + Nephew
-
Stryker
*Disclaimer: Major Players sorted in no particular order
3D Cardiac Mapping Systems Market News
- May 2024: Biosense Webster Inc., a cardiac arrhythmia treatment devices provider and part of Johnson & Johnson MedTech, launched the CARTO 3 System Version 8, the latest version of the company’s leading three-dimension (3D) heart mapping system used in cardiac ablation procedures.
- March 2023: Medtronic received a CE (Conformité Européenne) Mark for the Affer Mapping and Ablation System, including the Sphere-9 Catheter and the Affera Prism-1 Mapping Software.
3D Cardiac Mapping Systems Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and market definitions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Cardiovascular Diseases Coupled with the Rising Geriatric Population
4.2.2 Increasing Number of Technological Advancements
4.3 Market Restraints
4.3.1 High Cost of 3D Cardiac Mapping Systems
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Technology
5.1.1 Electroanatomical Mapping
5.1.2 Basket Catheter Mapping
5.1.3 Real-time Positional Management
5.2 By End User
5.2.1 Hospitals
5.2.2 Clinics
5.2.3 Diagnostic Centers
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Olympus Corporation
6.1.2 Medtronic
6.1.3 GE Healthcare
6.1.4 Siemens Healthineers AG
6.1.5 Smith + Nephew
6.1.6 Abbott
6.1.7 Intuitive Surgical Inc.
6.1.8 Koninklijke Philips NV
6.1.9 Stryker Corporation
6.1.10 Zimmer Biomet
- *List Not Exhaustive
3D Cardiac Mapping Systems Industry Segmentation
As per the scope of the report, 3D cardiac mapping system devices use mapping catheters to measure the electrical activity of cardiac tissue and create comprehensive three-dimensional electroanatomic mapping of your patients’ hearts. The 3D cardiac mapping system market is segmented into technology, end user, and geography. By technology, the market is segmented into electroanatomical mapping, basket catheter mapping, and real-time positional management. By end user, the market is segmented into hospitals, clinics, and diagnostic centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market sizing and forecasts are done based on value (in USD).
| By Technology | |
| Electroanatomical Mapping | |
| Basket Catheter Mapping | |
| Real-time Positional Management |
| By End User | |
| Hospitals | |
| Clinics | |
| Diagnostic Centers |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
3D Cardiac Mapping Systems Market Research FAQs
How big is the 3D Cardiac Mapping Systems Market?
The 3D Cardiac Mapping Systems Market size is expected to reach USD 538.60 million in 2024 and grow at a CAGR of 11.40% to reach USD 924.07 million by 2029.
What is the current 3D Cardiac Mapping Systems Market size?
In 2024, the 3D Cardiac Mapping Systems Market size is expected to reach USD 538.60 million.
Who are the key players in 3D Cardiac Mapping Systems Market?
Koninklijke Philips NV, Zimmer Biomet, Medtronic, Smith + Nephew and Stryker are the major companies operating in the 3D Cardiac Mapping Systems Market.
Which is the fastest growing region in 3D Cardiac Mapping Systems Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in 3D Cardiac Mapping Systems Market?
In 2024, the North America accounts for the largest market share in 3D Cardiac Mapping Systems Market.
What years does this 3D Cardiac Mapping Systems Market cover, and what was the market size in 2023?
In 2023, the 3D Cardiac Mapping Systems Market size was estimated at USD 477.20 million. The report covers the 3D Cardiac Mapping Systems Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the 3D Cardiac Mapping Systems Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
3D Cardiac Mapping Systems Industry Report
Statistics for the 2024 3D Cardiac Mapping Systems market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. 3D Cardiac Mapping Systems analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
